 the aging of the world population is expected to be accompanied by increased pneumococcal pneumonia in older adults . to address this , 
 the community - acquired pneumonia immunization trial in adults ( capita ) , a large , randomized , placebo - controlled trial conducted to assess the 13-valent pneumococcal conjugate vaccine ( pcv13 ) in adults 65  years , found statistically significant vaccine efficacy for first episodes of vaccine - type community - acquired pneumonia ( vt - cap ; 46% ) , nonbacteremic / noninvasive vt - cap ( 45% ) , and vt invasive pneumococcal disease ( 75% ) , along with an acceptable safety profile . 
 study results were presented to the us advisory committee on immunization practices in june 2014 , which subsequently recommended sequential pcv13 and 23-valent pneumococcal polysaccharide vaccination for adults 65  years . 
 thus , appropriate protection of adults at risk for pneumococcal cap will include vaccination with pcv13 . 
Funding